Introduced
Underlined text would be added to current law. Struck-through text would be removed.
| By: Harrison | H.B. No. 975 |
| A BILL TO BE ENTITLED | |
| AN ACT | |
| relating to the right to try cutting-edge treatments for patients | |
| with life-threatening or severely debilitating illnesses. | |
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | |
| SECTION 1. Title 6, Health and Safety Code, is amended by | |
| adding Subtitle C-1 to read as follows: | |
| SUBTITLE C-1. INVESTIGATIONAL TREATMENTS | |
| CHAPTER 491. ACCESS TO INDIVIDUALIZED INVESTIGATIONAL TREATMENTS | |
| FOR PATIENTS WITH LIFE-THREATENING OR SEVERELY DEBILITATING | |
| ILLNESSES | |
| SUBCHAPTER A. GENERAL PROVISIONS | |
| Sec. 491.001. DEFINITIONS. In this chapter: | |
| (1) "Individualized investigational treatment" means | |
| a drug, biological product, or device that is unique to and produced | |
| exclusively for use by an individual patient, based on the | |
| patient's genetic profile. The term includes individualized gene | |
| therapy antisense oligonucleotides and individualized neoantigen | |
| vaccines. | |
| (2) "Life-threatening illness" means a disease or | |
| condition with: | |
| (A) a significantly increased likelihood of | |
| death unless the course of the disease or condition is interrupted; | |
| or | |
| (B) potentially fatal outcomes and for which the | |
| goal of clinical trials is survival. | |
| (3) "Severely debilitating illness" means a disease or | |
| condition that causes major irreversible morbidity. | |
| SUBCHAPTER B. ACCESS TO INDIVIDUALIZED INVESTIGATIONAL TREATMENT | |
| Sec. 491.051. HEALTH CARE FACILITY ELIGIBILITY. A health | |
| care facility is eligible to provide an individualized | |
| investigational treatment under this chapter if the facility is | |
| operating under a federal assurance for the protection of human | |
| subjects under 42 U.S.C. Section 289(a) and 45 C.F.R. Part 46 and is | |
| subject to the federal assurance laws, regulations, policies, and | |
| guidelines and renewals or updates to the laws, regulations, | |
| policies, and guidelines. | |
| Sec. 491.052. PATIENT ELIGIBILITY. A patient is eligible | |
| to receive an individualized investigational treatment under this | |
| chapter if: | |
| (1) the patient: | |
| (A) has a life-threatening illness or severely | |
| debilitating illness; | |
| (B) has considered all other treatment options | |
| currently approved by the United States Food and Drug | |
| Administration; and | |
| (C) has given written informed consent for the | |
| use of the individualized investigational treatment; and | |
| (2) the patient's physician: | |
| (A) attests to the patient's life-threatening | |
| illness or severely debilitating illness and that the patient meets | |
| the requirements under this section; and | |
| (B) recommends an individualized investigational | |
| treatment for the patient based on analysis of the patient's | |
| genomic sequence, human chromosomes, deoxyribonucleic acid, | |
| ribonucleic acid, genes, gene products such as enzymes and other | |
| types of proteins, or metabolites. | |
| Sec. 491.053. INFORMED CONSENT. (a) An eligible patient | |
| may not receive an individualized investigational treatment unless | |
| the patient provides written informed consent. If the patient is a | |
| minor or lacks the mental capacity to provide informed consent, a | |
| parent, legal guardian, managing conservator, or patient's agent as | |
| defined by Section 166.151 may provide written informed consent on | |
| the patient's behalf. | |
| (b) Informed consent under this chapter must be attested to | |
| in writing by the patient's physician and a witness. | |
| (c) Informed consent under this chapter must include at a | |
| minimum: | |
| (1) an explanation of the currently approved products | |
| and treatments for the patient's disease or condition; | |
| (2) an attestation that the patient concurs with the | |
| patient's physician in believing that all currently approved and | |
| conventionally recognized treatments are unlikely to prolong the | |
| patient's life; | |
| (3) clear identification of the specific proposed | |
| individualized investigational drug, biological product, or device | |
| the patient's physician recommends; | |
| (4) a description, based on the physician's knowledge | |
| of the proposed treatment in conjunction with an awareness of the | |
| patient's disease or condition, of the potentially best and worst | |
| outcomes of using the individualized investigational treatment, | |
| and of the most likely outcome, including the possibility that new, | |
| unanticipated, different, or worse symptoms might result and that | |
| death could be hastened by the proposed treatment; | |
| (5) a statement that the patient's health benefit plan | |
| issuer or third-party administrator and provider are not obligated | |
| to pay the cost of any care or treatments related to the use of the | |
| individualized investigational treatment unless payment is | |
| specifically required by law or contract; | |
| (6) a statement that the patient's eligibility for | |
| hospice care may be withdrawn if the patient begins curative | |
| treatment with the individualized investigational treatment and | |
| that care may be reinstated if this treatment ends and the patient | |
| meets hospice eligibility requirements; and | |
| (7) a statement that the patient understands the | |
| patient is liable for all expenses related to the use of the | |
| individualized investigational treatment and the liability extends | |
| to the patient's estate, unless a contract between the patient and | |
| the manufacturer of the individualized investigational treatment | |
| states otherwise. | |
| Sec. 491.054. PROVISION OF TREATMENT; COSTS. (a) A | |
| manufacturer operating within an eligible health care facility and | |
| in compliance with all applicable federal assurance laws and | |
| regulations may make available an individualized investigative | |
| treatment, and an eligible patient may request to receive an | |
| individualized investigational treatment from an eligible health | |
| care facility or manufacturer operating within an eligible health | |
| care facility under this chapter. | |
| (b) A manufacturer is not required under this chapter to | |
| make available an individualized investigational treatment to an | |
| eligible patient. | |
| (c) An eligible health care facility or manufacturer | |
| operating within an eligible health care facility may: | |
| (1) provide an individualized investigational | |
| treatment to an eligible patient without receiving compensation; or | |
| (2) require an eligible patient to pay the costs of, or | |
| the costs associated with, the manufacture of the individualized | |
| investigational treatment. | |
| Sec. 491.055. DEBT LIABILITY ON DEATH OF PATIENT. If a | |
| patient dies while being treated under an individualized | |
| investigational treatment, the patient's heirs are not liable for | |
| any outstanding debt related to the treatment or lack of health | |
| coverage due to the treatment. | |
| Sec. 491.056. NO PRIVATE CAUSE OF ACTION. This chapter does | |
| not create a private cause of action against a manufacturer of an | |
| individualized investigational treatment or against any other | |
| person involved in the care of an eligible patient using the | |
| individualized investigational treatment for any harm to the | |
| eligible patient resulting from the individualized investigational | |
| treatment if the manufacturer or other person is complying in good | |
| faith with the terms of this chapter and has exercised reasonable | |
| care. | |
| Sec. 491.057. STATE MAY NOT INTERFERE WITH ACCESS TO | |
| TREATMENT. (a) An officer, employee, or agent of this state may | |
| not block or attempt to block an eligible patient's access to an | |
| individualized investigational treatment that complies with this | |
| chapter and rules adopted under this chapter. | |
| (b) Notwithstanding Subsection (a), counseling, advice, or | |
| a recommendation consistent with medical standards of care from a | |
| licensed health care provider is not a violation of this section. | |
| SUBCHAPTER C. HEALTH COVERAGE AND SERVICES | |
| Sec. 491.101. HEALTH COVERAGE. This chapter does not | |
| affect: | |
| (1) the coverage required of an insurer under the | |
| Insurance Code; or | |
| (2) health care coverage of enrollees in clinical | |
| trials under Chapter 1379, Insurance Code. | |
| Sec. 491.102. GOVERNMENTAL AGENCY NOT RESPONSIBLE FOR | |
| COSTS. This chapter does not require a governmental agency to pay | |
| costs associated with the use, care, or treatment of a patient with | |
| an individualized investigational treatment. | |
| Sec. 491.103. HOSPITAL SERVICES. This chapter does not | |
| require a hospital or health care facility licensed under Subtitle | |
| B, Title 4, to provide new or additional services unless approved by | |
| the hospital or facility. | |
| Sec. 491.104. COVERAGE OPTIONAL. A health benefit plan | |
| issuer, third-party administrator, or governmental agency may, but | |
| is not required to, provide coverage for the cost of an | |
| individualized investigational treatment or the cost of services | |
| related to the use of an individualized investigational treatment | |
| under this chapter. | |
| SUBCHAPTER D. HEALTH CARE PROVIDERS | |
| Sec. 491.151. PROHIBITED ACTION AGAINST LICENSE OR | |
| CERTIFICATION HOLDER. (a) A state licensing board may not revoke, | |
| fail to renew, suspend, or take any action against a health care | |
| provider's license issued under Title 3, Occupations Code, based | |
| solely on the health care provider's recommendation to an eligible | |
| patient regarding access to or treatment with an individualized | |
| investigational treatment. | |
| (b) The Health and Human Services Commission may not take | |
| action against a health care provider's Medicare certification | |
| based solely on the health care provider's recommendation that a | |
| patient have access to an individualized investigational | |
| treatment. | |
| SECTION 2. This Act takes effect September 1, 2025. |
Official text from the Texas Legislature. Formatting has been adapted for reading on Ratifi.